Fennec Pharmaceuticals (FENC) to Post Quarterly Earnings on Thursday

Fennec Pharmaceuticals (NASDAQ:FENC) is set to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 53.38%. The business had revenue of $7.26 million for the quarter, compared to analyst estimates of $13.67 million. During the same period last year, the firm earned ($0.21) earnings per share. On average, analysts expect Fennec Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Fennec Pharmaceuticals Trading Up 3.0 %

Shares of Fennec Pharmaceuticals stock traded up $0.14 during trading hours on Tuesday, hitting $4.79. The company’s stock had a trading volume of 56,024 shares, compared to its average volume of 112,186. The company has a quick ratio of 7.75, a current ratio of 8.02 and a debt-to-equity ratio of 9.86. The company has a market capitalization of $131.35 million, a PE ratio of 122.50 and a beta of 0.27. The business has a fifty day moving average of $4.92 and a 200 day moving average of $6.23. Fennec Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $11.92.

Analyst Ratings Changes

FENC has been the topic of a number of recent research reports. Craig Hallum reduced their price objective on Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. Wedbush reissued an “outperform” rating and set a $14.00 price target (down from $16.00) on shares of Fennec Pharmaceuticals in a research report on Tuesday, August 13th. Finally, HC Wainwright lowered their price objective on shares of Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, August 22nd.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.